Acetazolamide

Active ingredient description

Acetazolamide is an enzyme inhibitor which acts specifically on carbonic anhydrase. By inhibiting the reaction catalysed by this enzyme in the renal tubules, acetazolamide increases the excretion of bicarbonate and of cations, chiefly sodium and potassium, and so promotes alkaline diuresis. By inhibiting carbonic anhydrase in the eye acetazolamide decreases intra-ocular pressure and is therefore useful in the treatment of glaucoma.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Acetazolamide
S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EC Carbonic anhydrase inhibitors
Discover more medicines within S01EC01

Medicines

Acetazolamide is the active ingredient of these drugs:

Drug
Countries

Estonia

Estonia Germany

Estonia

Estonia Lithuania

Australia Austria Brazil Estonia France

Estonia Poland

Spain

Ecuador

New Zealand

Germany

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 222.245 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 59-66-5
DrugBank Drug: DB00819
KEGG Drug: D00218
RxNorm Ingredient: 167
SNOMED-CT Concept: 372709008
Acetazolamide (substance)
UNII Identifier: O3FX965V0I
ACETAZOLAMIDE